Venture Capital

Features

Exscientia raises $100m Series C funding to develop fully autonomous drug design

Exscientia has raised $100m in its second Series C in the past nine months. The round was led by BlackRock, but included existing investors: Novo Holdings and Evotec, among others. Exscientia plans to use the funding to advance its technology platforms towards autonomous drug design.

Features

Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake

Features

TCR-T cell therapies for cancer: TScan raises $100m in Series C round

Features

Disease-cancelling drugs: Immuneering raises $62m in Series B round

Features

Spotlight on rare neurological diseases: Noema closes $60.8m Series A round

Features

Investing in innovative biotechs with Novo Ventures

Deals

SynOx raises €37m in Series A to develop emactuzumab for rare cancer TGCT

Features

Araris raises CHF15.2m to support its next-gen ADCs

Deals

Spotlight on rare NMOSD: Chord launches with $16m Series A round

Deals

Targeting PP2A to tackle cancers: Rappta closes €9m Series A round

Deals

Targeting the tumour stroma: Phenomic AI launches with $6m seed financing

Features

Tackling fibrosis: Galecto raises $64m in equity financing

Features

Next-gen gene editing: Graphite Bio launches with $45m funding

Features

Powering biologics development with spirulina: Lumen closes $16m Series B

Features

Advancing AAV gene therapy: Forge closes $40m Series A

Features

Linking cancer and fibrosis: iOnctura raises €20.1m in a Series A round

Features

Selva raises $3m to develop novel antiviral against Covid-19

Features

Transforming gliobastoma treatment: Imvax closes $112m Series C round

Features

Investing in late-stage companies: Forbion closes Growth Fund at €185m

Features

Exploring the promise of DUBs: Mission teams up with Pfizer

Features

Off-the-shelf NK cell therapies: Artiva closes $78m Series A round

Features

Autobahn Labs: virtual incubator launches with a focus on academia

Features

Eir Ventures launches to unlock the potential of the Nordics

Features

Ona’s €30m Series A round: directly targeting metastasis in cancer

Features

C4T raises $170m for human trials of degrader drugs

Features

Novo Ventures gives the nod to NodThera’s inflammatory disease innovations

Features

Spotlight on BaseLaunch: fostering innovative start-ups in Basel

Features

Promise of AI in drug discovery: Exscientia raises $60m in Series C round

Features

Covid-19 pandemic: overcoming big pharma’s infectious disease market failure

Features

Atea closes $215m Series D round to support Covid-19 trials

Features

Rapid Micro Biosystems raises $120m: improving contamination testing in pharma

Features

Three big pharma VC arms bet on FoRx’s novel cancer approach

Deals Analysis

Asia-Pacific witnesses 5.4% increase in deal activity during week ended 19 April 2020

Deals Analysis

Breakthrough in neurodegeneration: GV, Bill Gates and Foresight invest $45m in Cerevance

Deals Analysis

Global deal activity decreases 17.2% with 899 deals last week

Deals Analysis

Healthcare sector sees growth in deal activity for second consecutive week

Deals Analysis

Covid-19 impact: Global VC funding activity continues to remain subdued

Deals Analysis

Healthcare sector witnesses growth in deal activity despite Covid-19 concerns